Moderna CFO Quits After Only One Day on the Job -- And Cashes Out With His Entire First-Year Salary The biotech company announced that Jorge Gomez was leaving his position, effective immediately.

By Emily Rella

Maddie Meyer/Getty Images
Maddie Meyer/Getty Images

Talk about a quick dash after securing the cash!

On Wednesday, pharmaceutical company Moderna announced that its CFO Jorge Gomez left after only one day on the job — but he'll still be collecting his full 12-month salary.

Prior to accepting his position at Moderna, Gomez served as the Executive Vice President & Chief Financial Officer of Dentsply Sirona Inc. since August 2019.

"The announcement follows the May 10 public disclosure by Mr. Gomez's former employer, Dentsply Sirona Inc., of an ongoing internal investigation into certain matters, including financial reporting," Moderna said in a company statement.

The internal probe in question will determine whether or not incentives that were used to help sell the dental supplier's products to widespread distributors were "properly accounted for," per CNBC.

Gomez' departure is effective immediately, with recently retired former CFO of the company, David Meline, filling in the position during the interim hiring process of a new candidate.

Related: Moderna Shares Spike After Company Says Its Covid Booster Increases Antibody Levels Against Omicron

Gomez was announced as Moderna's new CFO on April 11, with the position going into effect on May 9.

"It is a privilege for me to join an organization that is focused on developing transformative medicines to address major public healthcare challenges worldwide," Gomez said at the time. "I look forward to working with the team on this great mission."

Gomez' will still receive his $700,000 salary though he will no longer be eligible for his signing bonus or future bonuses within the one-year period.

Denstsply Board member and former Hillrom CEO John Groetelaars is currently serving as interim CEO.

The news comes after the April 19 announcement from Dentsply CEO Don Casey had been terminated from his position with the company after four years, three weeks before the company announced its less-than-stellar Q1 2022 earnings.

"The first quarter was a challenging quarter, and our financial performance and revised outlook reflect the impact of larger-than-expected macroeconomic headwinds and lower-than-expected performance in the United States," interim CEO Groetelaars told shareholders.

Moderna, on the other hand, had an exceptional first quarter, tripling Covid vaccine sales to an estimated $5.9 billion in revenue which sent shares skyrocketing over 7% in Wednesday's premarket trading.

Related: Moderna Says Its Vaccine Is 96% Effective in Teens

Emily Rella

Entrepreneur Staff

Senior News Writer

Emily Rella is a Senior News Writer at Previously, she was an editor at Verizon Media. Her coverage spans features, business, lifestyle, tech, entertainment, and lifestyle. She is a 2015 graduate of Boston College and a Ridgefield, CT native. Find her on Twitter at @EmilyKRella.

Editor's Pick

Related Topics

Business News

Jeff Bezos Lost $5 Billion in 1 Day After Amazon FTC Lawsuit News

The lawsuit accuses Amazon of engaging in anticompetitive practices, which has led to a sharp decline in the company's stock value and a substantial reduction in Bezos's net worth.

Business News

Katy Perry Is Fighting the Founder of 1-800-Flowers for a $15 Million California Mansion He Doesn't Want to Sell Her

The eight-bedroom, 11-bathroom estate sits on nearly nine acres in the Santa Ynez foothills in Montecito.

Growing a Business

So Your Company Is Talking About Transformation — But Is It Ready? Here's How To Tell.

Transformation is one of a company's many choices — but if a team opts to do it, they have to be sure the business is ready, willing and able.